Results 271 to 280 of about 130,425 (315)
Some of the next articles are maybe not open access.
Therapeutics Targeting Mutant KRAS
Annual Review of Medicine, 2021Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the downstream effectors of EGFR activation, regulating cellular switches and functions and triggering intracellular signaling cascades such as the MAPK and PI3K pathways.
Kyaw Z, Thein +2 more
openaire +2 more sources
European Journal of Cancer, 2009
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab have been demonstrated to be efficient in the treatment of irinotecan-resistant and chemorefractory metastatic colorectal cancer (mCRC) respectively. However, these costly and potentially toxic treatments are only efficient in a small proportion of patients.
Pierre, Laurent-Puig +2 more
openaire +2 more sources
The anti-epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab have been demonstrated to be efficient in the treatment of irinotecan-resistant and chemorefractory metastatic colorectal cancer (mCRC) respectively. However, these costly and potentially toxic treatments are only efficient in a small proportion of patients.
Pierre, Laurent-Puig +2 more
openaire +2 more sources
KRAS mutations: Analytical considerations
Clinica Chimica Acta, 2014Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer death globally. Significant improvements in survival have been made in patients with metastasis by new therapies. For example, Cetuximab and Panitumumab are monoclonal antibodies that inhibit the epidermal growth receptor (EGFR).
Marta Herreros-Villanueva +4 more
openaire +2 more sources
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
Molecular Cancer TherapeuticsAbstract Pancreatic ductal adenocarcinoma (PDAC) is associated with significant morbidity and mortality and is projected to be the second leading cause of cancer-related deaths by 2030. Mutations in KRAS are found in the vast majority of PDAC cases and plays an important role in the development of the disease.
Minh T. Than +3 more
openaire +2 more sources
KRAS mutation: from undruggable to druggable in cancer
Signal Transduction and Targeted Therapy, 2021Liwu Fu
exaly
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Nature Reviews Cancer, 2021Samuel Andrew Kerk +2 more
exaly